Envelope
For further information, please contact us on 01249 466 966, Monday to Friday 9am-5.30pm, or email us

How does Gelclair® work?
Gelclair® is a viscous gel specially formulated to aid in the management of lesions of the oral mucosa. It forms a protective film that, by adhering to the mucosa of the oropharyngeal cavity, offers rapid and effective pain management.9 It is presented as a concentrated gel in sachets for dilution with water.
  • Gelclair® contains PVP (polyvinylpyrrolidone) and sodium hyaluronate in a liquid gel.
  • When washed around the mouth these agents combine to form a bioprotective coating that adheres to the lining of the mouth.
  • The bioprotective coating offers rapid and effective pain management.9−11
  • Pain is significantly reduced following the first administration of Gelclair®.9
  • Gelclair® can potentially improve the ability to eat and drink and, unlike preparations with an alcohol or anaesthetic base, does not sting on application.9
Indications Show/Hide

Gelclair® helps in the management of lesions of the oropharyngeal cavity. Gelclair® forms a protective film that helps to provide pain relief, soothing mouth lesions including those caused by medication, disease, radiotherapy, chemotherapy, oral surgery, traumatic ulcers caused by dental braces and dentures, and ageing.

Hide
How to use Gelclair® Show/Hide

Frequency of use
Gelclair<sup>®</sup> should be used 3 times daily or as needed Gelclair® should be used 3 times daily or as needed
Use 30-60 minutes before eating or drinking Use 30-60 minutes before eating or drinking
Instructions for use
Tear along top of the sachet Tear along top of the sachet
Squeeze the Gelclair<sup>®</sup> into a glass Squeeze the Gelclair® into a glass
Add about 3 tablespoons of water (40ml) and stir well Add about 3 tablespoons of water (40ml) and stir well
Use as a mouthwash straight away – rinsing around the mouth for at least 1 minute, or for as long as possible to coat the tongue and inside of the mouth completely Use as a mouthwash straight away - rinsing around the mouth for at least 1 minute, or for as long as possible to coat the tongue and inside of the mouth completely
Gargle and spit out Gargle and spit out

If no water is available, Gelclair® is safe to use undiluted - applied directly with a sponge or swab

Throw away any unused Gelclair® mouthwash


Hide
Clinical evidence

Gelclair®: potentially an efficacious treatment for chemotherapy-induced mucositis
De Cordi D, Martina S.
Presented at the Third Italian Anti-Tumour League Congress for Professional Oncology Nurses, Conegliano, Italy, 10−12 October 2001. Show/Hide

Study outline
Thirty patients with chemotherapy-induced oral mucositis were evaluated for pain, functionality (ability to eat and drink) and grade of oral mucositis, at baseline, 1 day and 3 days after taking Gelclair®.

Results
  • Pain: 83% reported a reduction in pain, 13% remained the same and 3% showed initial improvement but then got worse.
  • Ability to eat and drink: 83% showed distinct improvement, 7% remained the same, 7% got worse, while 3% reported considerable improvement followed by slight worsening.
  • Grade of mucositis: 57% improved, 40% remained the same, 3% got worse.
Patients' pain response graph
Patients' functional ability graph
Mucositis changes graph


Note: P values not stated by investigators



Hide
Efficacy of Gelclair® in reducing pain in patients with oral lesions − preliminary findings from an open pilot study
Innocenti M, Moscatelli G, Lopez S.
J Pain Symptom Manage 2002; 24(5): 456−457 Show/Hide

Study outline
Thirty patients with painful lesions of the mouth and oropharynx (caused by various diseases) were evaluated for short term (5−7 hours) and medium term (7−10 days) effects of Gelclair® on the severity of pain on swallowing and eating.

Results
A significant reduction in pain scores was observed both in the short term and medium term following administration of Gelclair®. In this 10 day trial, results indicated that Gelclair® rapidly and effectively reduces pain associated with oral lesions (e.g. oral mucositis), and can improve nutrition, with continued use.

Reduction in pain graph


Hide
A preliminary study of Orassist (Gelclair®) in the management of oral mucositis
Berndtson M.
Svensk Sjukhustandlakartidning {Swedish Hospital Dentistry} 2001; 26(3): 17–21. Show/Hide

Study outline
Ten patients were given Gelclair® to evaluate its effect on their symptoms of oral mucositis.

Results
All reported that the product was acceptable for its taste and consistency, and a palliative soothing effect was noted.

Hide
An audit of the efficacy of Gelclair® for mouth pain in patients undergoing radiotherapy or chemotherapy
McLean M.
Poster presented at the British Association of Head and Neck Oncology Nurses National Study Day on Sharing Good Practice in Head and Neck Cancer Nursing, 12 June 2009. Show/Hide

Study outline
Twenty−six patients with Grade 2 oral mucositis were given Gelclair® to evaluate its effect on reducing the pain of oral mucositis, increasing functionality and reducing the need for concomitant analgesic consumption. Results were obtained for 16 patients who completed the full 7−day study.

Results
  • Pain: by the end of day 3, the average pain score had reduced from 6.6 before treatment to 4.2, a reduction of 36% (p=0.0021).
  • Pain: by the end of day 7, the average pain score had decreased from 6.6 to 2.4, a decrease of 4.2 points, signifying an average pain score reduction of 63% at the end of the 7−day assessment period (p<0.0001).
  • Analgesic consumption: by the end of day 7, the average number of analgesic doses had reduced to 2.4, an average reduction of 43% (p=ns).
  • Functionality: Gelclair® treatment enabled a more comfortable intake of food and fluids by the end of day 7, functionality scores were reduced by an average of 17% (p=ns).
Average pain score in Gelclair-treated cancer patients graph


Hide
Reporting of side effects

Medical device adverse incidents should be reported to the MHRA. Reporting information can be found at www.mhra.gov.uk. Any adverse event should also be reported to Pharm acovigilance at Alliance Pharmaceuticals Limited (tel: 01249 466 966, email:pharmacovigilance@alliancepharma.co.uk).
Find out more about the effects of oral mucositis on patients' lives
Jacqueline
To watch videos of other people's experiences with oral mucositis, click here
This animation shows how Gelclair can help to relieve the pain of oral lesions and ulcers caused by oral mucositis.
Tell friends about Gelclair which helps to relieve the pain of oral lesions and ulcers from oral mucositis.
For further information, please contact us on 01249 466 966, Monday to Friday 9am-5.30pm, or email us

You are now leaving the UK healthcare professionals section of the website.

You will be returned to the public section of the website.

OK